Literature DB >> 33609274

Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms.

Samuel Kohtala1,2,3.   

Abstract

Over the past 50 years, ketamine has solidified its position in both human and veterinary medicine as an important anesthetic with many uses. More recently, ketamine has been studied and used for several new indications, ranging from chronic pain to drug addiction and post-traumatic stress disorder. The discovery of the rapid-acting antidepressant effects of ketamine has resulted in a surge of interest towards understanding the precise mechanisms driving its effects. Indeed, ketamine may have had the largest impact for advancements in the research and treatment of psychiatric disorders in the past few decades. While intense research efforts have been aimed towards uncovering the molecular targets underlying ketamine's effects in treating depression, the underlying neurobiological mechanisms remain elusive. These efforts are made more difficult by ketamine's complex dose-dependent effects on molecular mechanisms, multiple pharmacologically active metabolites, and a mechanism of action associated with the facilitation of synaptic plasticity. This review aims to provide a brief overview of the different uses of ketamine, with an emphasis on examining ketamine's rapid antidepressant effects spanning molecular, cellular, and network levels. Another focus of the review is to offer a perspective on studies related to the different doses of ketamine used in antidepressant research. Finally, the review discusses some of the latest hypotheses concerning ketamine's action.

Entities:  

Keywords:  Anesthesia; Depression; Dose; Ketamine; Rapid-acting antidepressant; Subanesthetic

Year:  2021        PMID: 33609274      PMCID: PMC7994242          DOI: 10.1007/s43440-021-00232-4

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  245 in total

1.  A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.

Authors:  Elias Dakwar; Edward V Nunes; Carl L Hart; Richard W Foltin; Sanjay J Mathew; Kenneth M Carpenter; C J Jean Choi; Cale N Basaraba; Martina Pavlicova; Frances R Levin
Journal:  Am J Psychiatry       Date:  2019-06-24       Impact factor: 18.112

2.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

3.  Ketamine for procedural sedation and analgesia by nonanesthesiologists in the field: a review for military health care providers.

Authors:  Gregory T Guldner; Bruno Petinaux; Peter Clemens; Stanley Foster; Scott Antoine
Journal:  Mil Med       Date:  2006-06       Impact factor: 1.437

4.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

5.  Depression, rumination and the default network.

Authors:  Marc G Berman; Scott Peltier; Derek Evan Nee; Ethan Kross; Patricia J Deldin; John Jonides
Journal:  Soc Cogn Affect Neurosci       Date:  2010-09-19       Impact factor: 3.436

6.  Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

Authors:  Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2012-04-21       Impact factor: 13.382

7.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

8.  Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study.

Authors:  Nour Azhari; Helen Hu; Kate Y O'Malley; Megan E Blocker; Frances R Levin; Elias Dakwar
Journal:  Am J Drug Alcohol Abuse       Date:  2020-11-11       Impact factor: 3.829

9.  Perioperative intravenous ketamine for acute postoperative pain in adults.

Authors:  Elina Cv Brinck; Elina Tiippana; Michael Heesen; Rae Frances Bell; Sebastian Straube; R Andrew Moore; Vesa Kontinen
Journal:  Cochrane Database Syst Rev       Date:  2018-12-20

10.  Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.

Authors:  Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2020-02-24       Impact factor: 7.853

View more
  5 in total

Review 1.  Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability.

Authors:  Michael D Kritzer; Chi-Un Pae; Prakash S Masand
Journal:  Expert Opin Drug Saf       Date:  2022-04-29       Impact factor: 4.011

2.  Editorial: Ketamine for treatment of acute and chronic pain: The relationship of mechanism and exposure to therapeutic outcome.

Authors:  Albert Dahan; Thomas K Henthorn
Journal:  Front Pain Res (Lausanne)       Date:  2022-08-23

3.  S-Ketamine oral thin film-Part 2: Population pharmacodynamics of S-ketamine, S-norketamine and S-hydroxynorketamine.

Authors:  Pieter Simons; Erik Olofsen; Monique van Velzen; Maarten van Lemmen; Tom van Dasselaar; Patrick Mohr; Florian Hammes; Rutger van der Schrier; Marieke Niesters; Albert Dahan
Journal:  Front Pain Res (Lausanne)       Date:  2022-08-11

Review 4.  Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies.

Authors:  Luigi La Via; Filippo Sanfilippo; Giuseppe Cuttone; Veronica Dezio; Monica Falcone; Serena Brancati; Claudia Crimi; Marinella Astuto
Journal:  Eur J Clin Pharmacol       Date:  2022-08-26       Impact factor: 3.064

5.  Post-Partum Depression Lactating Rat Model for Evaluating Ketamine's Safety as a Pharmacotherapeutic Treatment: Roles in Cardiac and Urinary Function.

Authors:  André Rinaldi Fukushima; Pedro Enrique Navas-Suárez; Juliana Weckx Peña Muñoz; Esther Lopes Ricci; Luís Antônio Baffile Leoni; Érico C Caperuto; Leandro Yanase; Jeferson Santana; Elias de França; Jan Carlo Morais O Bertassoni Delorenzi; Alcides Felix Terrivel; Gláucio M Ferreira; Mario Hiroyuki Hirata; Lorena de Paula Pantaleon; Julia Zacarelli-Magalhães; Gabriel Ramos de Abreu; Paula A Faria Waziry; Maria Aparecida Nicoletti; Helenice de Souza Spinosa
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.